Aurora Cannabis Inc. (ACB) shares soared 46% in the last trading session to close at $9.23. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 46.6% gain over the past four weeks.The sharp upsurge in Aurora's shares can be attributed to the DEA's reported decision to reclassify marijuana from Schedule I (reserved for drugs with a high potential for abuse) to Schedule III (reserved for drugs with a moderate to low potential for physi ...

The US is planning to reclassify cannabis as a less dangerous drug in an historic shift that could have a significant impact across the country.The Drug Enforcement Administration's (DEA) proposal would recognise the drug's medical properties and acknowledge it has less potential for abuse than other dangerous substances. However the proposal, which still must be reviewed by the White House, would not legalise cannabis outright for recreational use.Marijuana is currently classified in the US as a "schedule ...

Cannabis stocks soared nearly across the board this afternoon on news that President Joe Biden’s administration is moving to reschedule marijuana as a Schedule III substance, a less severe designation than its prior Schedule I classification. Indeed, acting on a review from the Department of Health and Human Substances, the U.S. Drug Enforcement Administration (DEA) and U.S. Justice Department may recategorize cannabis as early as this week. A move to Schedule III would yield major benefits to both the lega ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The new dried flowers, including Black Jelly, Chemango Kush, and Moon Berry, are proprietary cultivars cultivated exclusively by Aurora. Vespera, a previously existing proprietary cultivar, is also set for relaunch under the Aurora brand. These products mark a significant step forward for MedReleaf Australia as they continue to expand their offerings under the Aurora brand.  The dried flower products are available now in four 10g formats including: Aurora Moon Berry T9/C13 Balanced Aurora Black Jelly T28 ...

Industry Overview - The global cannabis industry is expected to experience significant growth, with a projected compound annual growth rate of over 20% for the next decade, driven by increasing legalization and medical use [1] - Canadian cannabis stocks have shown impressive performance recently, with several stocks achieving double-digit gains, indicating growing investor confidence in the sector [2] Company Highlights: Aurora Cannabis Inc. - Aurora Cannabis Inc. is recognized for its commitment to quality and innovation, with operations including multiple facilities and research centers across Canada [3] - The company has strategically entered the U.S. market by acquiring Reliva, LLC, a leader in hemp-derived CBD products, which helps Aurora leverage an established distribution network despite federal restrictions on THC products [5] - For Q3 FY2024, Aurora reported consolidated revenue of $64.4 million, up from $61.1 million the previous year, with adjusted gross profit rising to $32.4 million, a 15.7% increase [6][7] - Medical cannabis accounted for 70% of Aurora's consolidated revenue and 86% of adjusted gross profit, with notable sales increases in Australia and Europe [7] - The company reduced its net loss to $25.2 million from $62.4 million the previous year, highlighting effective cost management and operational improvements [8] Company Highlights: Canopy Growth Corporation - Canopy Growth Corporation is a leader in the global cannabis industry, known for producing high-quality cannabis products for both medicinal and recreational use [9] - The company has rapidly expanded its production and retail sites in Canada and strategically established a presence in U.S. states with cannabis-friendly laws [11] - Canopy Growth reported a combined gross margin of 36% for Q3 FY2024, with cannabis gross margins in Canada increasing to 28% from a negative 11% in the previous year [13] - The company's net revenue for the quarter was $79 million, a 7% decrease from the previous year, but cannabis revenue outside of Australia surged by 81% [14] - Canopy Growth achieved a $34 million improvement in free cash flow from ongoing operations, marking a 57% increase, and reported a healthy balance of $186 million in cash and short-term investments [15] Future Outlook - Canadian cannabis companies like Canopy Growth and Aurora Cannabis are well-positioned for future growth, particularly with their expansion efforts into international markets, including the U.S. [16] - The U.S. cannabis industry is expected to expand significantly, presenting lucrative opportunities for Canadian companies operating in the American market [17]

Industry Overview - Cannabis stocks are becoming increasingly profitable, with Canopy Growth (CGC) rising from $2.75 to $11.57 recently, currently at $6 [1] - Public support for cannabis legalization in the U.S. is at 88%, with potential legalization in Florida and Germany's recent legalization possibly influencing Europe [1] Company Analysis: Innovative Industrial Properties (IIPR) - IIPR is currently oversold at $94.23 and has a yield of 7.73% [2] - Recent earnings showed funds from operations (FFO) at $2.07, exceeding expectations, and revenue at $79.2 million, up from $70.5 million year-over-year [3] - The company collected 100% rent in the last quarter, and cannabis rescheduling could enhance cash flow for IIPR tenants [3] Company Analysis: Trulieve Cannabis (TCNNF) - TCNNF is trading at $10.74, with a potential target of $13.75 [5] - If Florida legalizes adult-use cannabis, it could significantly impact Trulieve, with the state's medical marijuana market projected to generate $2 billion annually [5] - Trulieve funded $40 million for the legalization initiative and has increased its retail locations to 192 [5] Company Analysis: Aurora Cannabis (ACB) - ACB has seen a price increase from around $3 to $8.88, currently at $6.46, with potential growth linked to the Florida legalization vote [6] - The company is on track for its strongest fiscal year, with five consecutive quarters of positive adjusted EBITDA and significant international revenue growth [7]

Aurora Cannabis Inc. (ACB) closed the latest trading day at $6.46, indicating a -1.15% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.88%. At the same time, the Dow added 0.56%, and the tech-heavy Nasdaq lost 2.05%.Coming into today, shares of the company had gained 70.18% in the past month. In that same time, the Medical sector lost 6.4%, while the S&P 500 lost 2.57%.The investment community will be closely monitoring the performance of Aurora Cannabis Inc. in its fo ...

Core Insights - Canadian marijuana stocks are gaining investor attention due to ongoing developments in the global cannabis market, with companies like Tilray, Canopy Growth, and Aurora Cannabis leading the way [1][2] Company Summaries Canopy Growth Corporation - Canopy Growth is recognized for its commitment to quality and innovation, offering a diverse range of cannabis products for medical and recreational use [3][6] - The company has expanded its retail locations and production facilities, establishing a strong presence in Canada and key U.S. states like Colorado and California [5][6] - Financially, Canopy Growth reported a gross margin improvement to 28% from -11% year-over-year, with total net revenue of $79 million, a 7% decline from the previous year, but a significant 81% increase in international cannabis revenue [7][8] Tilray, Inc. - Tilray is a prominent player in the global cannabis industry, focusing on research, cultivation, and distribution across medical and adult-use markets [9][10] - The company achieved a 30% increase in net revenue to $188.3 million, with cannabis revenue rising by 33% to $63.4 million, despite a net loss of $105 million, reduced from $1.2 billion the previous year [10][11] - Tilray is actively reducing debt and improving liquidity, with a focus on diversifying its portfolio through strategic acquisitions [11][12] Aurora Cannabis Inc. - Aurora Cannabis has established a strong reputation in the cannabis industry, focusing on both medical and recreational markets [13][15] - The company reported consolidated revenue of $64.4 million, up from $61.1 million, driven by global medical cannabis growth, with adjusted gross margins expanding to 50% [16][17] - Aurora has reduced its net loss to $25.2 million from $62.4 million the previous year, with expectations of continued positive adjusted EBITDA into the fourth quarter of 2024 [17] Industry Overview - The global cannabis industry is on a growth trajectory, particularly in the U.S., driven by legal reforms and increasing social acceptance [2][19] - The potential for U.S. federal legalization could significantly boost the market, opening up interstate commerce and larger-scale operations [19] - Investors are advised to monitor technical analysis and maintain a diversified portfolio to capitalize on growth opportunities while managing risks [2][18]

If even Tilray can't make money from marijuana, what hope does any company have?Tuesday is turning into a lousy day to own marijuana stocks, as bad news from cannabis company Tilray Brands (TLRY -19.30%) is taking a toll on pretty much every other marijuana stock out there. Tilray reported a miss on sales this morning and a $0.12 per-share net loss.Shares of Cronos Group (CRON -1.86%), Canopy Growth (CGC -8.74%), and Aurora Cannabis (ACB -8.55%) are all suffering as a result, down 3.5%, 7.8%, and 8.5%, resp ...